ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Galapagos Signs Two Discovery Pacts

by Patricia L. Short
April 27, 2009 | APPEARED IN VOLUME 87, ISSUE 17

Belgian biotech firm Galapagos has entered two new drug discovery collaborations. One is a multiyear alliance with Merck & Co. to develop inflammatory disease treatments. Galapagos will be responsible for the discovery and preclinical development of new small-molecule drugs based on novel Galapagos targets. Merck will pay Galapagos an upfront fee of more than $3 million and milestone payments that could reach $250 million. In the other agreement, Galapagos' BioFocus DPI division will provide biology, medicinal chemistry, and analytical services to Ireland's Opsona Therapeutics. Opsona will fund the work of up to five researchers this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment